Abdominal cavity disorder after Trilostane (Vetoryl) in dogs

20 reports to the FDA describe abdominal cavity disorder in dogs given Trilostane. That is 0.2% of all reports for this medicine, compared with 0.0% across reports for all dog medicines, so it is reported unusually often with this medicine.

20Reports

75%Marked serious

5.0%Recovered

35%Died or euthanised

51 daysTypical onset

How soon it started

Same day

1 6.3%

1–2 days

1 6.3%

3–7 days

1 6.3%

1–4 weeks

3 19%

Over a month

10 63%

How the animals did

Recovered

1 5.0%

Still unwell when reported

1 5.0%

Died

2 10%

Euthanised

5 25%

Not known

11 55%

Problems reported at the same time

10 50%

8 40%

7 35%

7 35%

7 35%

Abnormal ultrasound finding

7 35%

Elevated gamma-glutamyl transferase (ggt)

6 30%

Weight loss

6 30%

Age of the animals

Under 1 year

1–3 years

4–7 years

8–11 years

12+ years

About this medicine

Trilostane treats Cushing's disease (an overactive adrenal gland).

Products with this ingredient include Vetoryl. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.

Questions owners ask

Can Trilostane cause abdominal cavity disorder in dogs?: 20 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
How soon after a dose was it reported?: In half of the reports with dates, it started within 51 days of the first dose.
What should I do?: Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).

All reported side effects of Trilostane in dogs · Medicines most reported with abdominal cavity disorder